



Human Infection Studies: Considerations on manufacturing of challenge agents - viruses (SARS-CoV-2/COVID-19) and parasites as examples

A Joint Wellcome Trust/HIC-Vac, hVIVO and IABS webinar
March 31, 2021 - CET

	Session	Speaker
15:00-15:05	IABS Welcome	Joris Vandeputte/Pieter Neels, IABS
	Chairs of the Webinar	Isabelle Bekeredjian-Ding, PEI Jean-Hugues Trouvin, IABS
15:05-15:10	Manufacturing Guidance Project	Carine La, hVIVO
15:10-15:25	General considerations	Hilde Depraetere, EVI
15:25-15:45	Challenge agent selection and characterisation, including adventitious agent testing	Eddie Suvarnapunya, WRAIR
15:45-16:00	Manufacturing and Control	Alan Bell, hVIVO
16:00-16:10	Routine production: which standard?	Jean-Hugues Trouvin, IABS
16:10-16:20	Break	
16:20-16:40	COVID-19 as relevant example	Pauline Meij, LUMC
16:40-17:00	Hookworm as second relevant example	Jeff Bethony and Linda Schellhaas, GWU
17:00-18:00	Round table discussion: <ul style="list-style-type: none">• Industry partners• Regulators (FDA/EMA/PEI/HC/...) Audience Q&A	Winfred Badanga, UNCST Uganda Hilde Depraetere, EVI Eric Karikari-Boateng – FDA Ghana Alex Mann, hVivo Pauline Meij, LUMC Jetsumon Prachumsri, Mahidol University Paula Salmikangas NDA Dean Smith, Health Canada Scott Stibitz, FDA Peter Stjarkvist, MPA Jean-Hugues Trouvi, IABS Wim Van Molle, Sciensano
18:00-18:15	Survey & Conclusions	